A year in review: clinical progress and positive feedback
Welcome to Oncolytics Insights. Here we will provide commentary on recent news, presentations and happenings related to Oncolytics and our development programs.
Cohort 1 demonstrated widespread viral replication in the majority of tumors with the creation of a pro-inflammatory effect in the tumor microenvironment.
Data presented by academic collaborators from Cancer Research UK at the International Oncolytic Viral Conference demonstrate synergistic activity between pelareorep and CDK4/6
KOL Call Highlights Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
Safety cohort in the investigator sponsored multiple myeloma study, receiving both carfilzomib and Opdivo®, is now complete and pelareorep will be added to the combination in the next cohort in the coming weeks
Interested in learning more about what we’ve been up to during the past few months? Last week, CEO Matt Coffey, provided an update on recent Oncolytics Biotech activities during our Q3 earnings call.
October marks Breast Cancer Awareness Month. Our CEO, Matt Coffey, Ph.D., shares his thoughts on why we need to raise awareness of one of the most common cancers, which affects approximately 1 in 8 women in the United States alone.
Through IV deliver, pelareorep can train the immune system to engage, target and kill tumor cells . . .
Although immuno-oncology has transformed how we treat many cancers today, there are still huge roadblocks the biopharma industry must overcome before I-O therapies can reach their full potential.
Educating the Immune System to Target Disease and Send Natural Killer Cells
Matt Coffey recently spoke with Bud Wayne of CEOCFO Magazine to recount our founding story . . .
The phase 2 BRACELET-1 study will evaluate Oncolytics' pelareorep in combination with anti-PD-L1 BAVENCIO®. Despite the surge of novel immuno-oncology drugs, many patients still face resistance.